InventisBio Reports Encouraging Phase III Results for Nomelcitinib in Psoriasis Treatment#China#Shanghai#InventisBio#TYK2_Inhibitor#Nomelcitinib
InventisBio Reports Encouraging Phase III Results for Nomelcitinib in Psoriasis Treatment
InventisBio has announced promising Phase III trial results for nomelcitinib in treating moderate to severe plaque psoriasis, showcasing significant efficacy and safety.
third-news.com
November 2, 2026 at 11:15 AM
InventisBio Reports Encouraging Phase III Results for Nomelcitinib in Psoriasis Treatment#China#Shanghai#InventisBio#TYK2_Inhibitor#Nomelcitinib
Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases#USA#Boston#Lynk_Pharmaceuticals#LNK01006#TYK2_Inhibitor
Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases
Lynk Pharmaceuticals announces FDA IND approval for LNK01006, a novel allosteric TYK2 inhibitor, opening doors to new therapies for neuroinflammatory diseases.
third-news.com
December 2, 2025 at 12:25 PM
Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases#USA#Boston#Lynk_Pharmaceuticals#LNK01006#TYK2_Inhibitor